Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study.

Vincent LangloisAndré GillibertYurdagul UzunhanMarie-Laure ChabiEric HachullaOcéane Landon-CardinalKuberaka MariampillaiNicolas ChamptiauxHilario NunesOlivier BenvenisteBaptiste Hervier

Published in: The Journal of rheumatology (2020)

Despite similar PFS at 6 months, RTX was associated with a better 2-year PFS compared to CYC in patients with AS-related ILD.

Keyphrases

interstitial lung disease
systemic sclerosis
rheumatoid arthritis
idiopathic pulmonary fibrosis
low dose
diffuse large b cell lymphoma
case report
cross sectional
chronic lymphocytic leukemia